Everything below concerns Semax. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-15. Numbers and descriptions here follow the published literature rather than marketing material.
The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.
Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | ~813.9 Da (free heptapeptide) | N-acetylated form is about 42 Da heavier |
| Residue count | 7 (heptapeptide) | Four residues from ACTH(4-10), three added |
| Appearance | White to off-white powder | Usually supplied lyophilized |
| Solubility class | Freely soluble in water | Also dissolves in DMSO and polar organic solvents |
| Related parent fragment | ACTH(4-10) | Parent motif is Met-Glu-His-Phe |
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
He also receives further instruction from Morpheus on subjects such as "freeing his mind" from the restrictions of the Matrix, essentially overcoming the physics engine the Matrix operates on. He is also informed of the existence of its agents, programs designed by the machines to maintain order and dominance over the human race, created with abilities such as dodging bullets, running at high speeds, jumping great distances, and physically possessing people in the Matrix. If killed, they simply find a new host to overcome. After several days aboard Morpheus' hovercraft, the Nebuchadnezzar, Neo is taken to meet the Oracle, who has the power of foresight within the simulated world. She tells him that he has the "gift", but appeared to be waiting for something, and that in his present life he is not the One. The Oracle warns him that a situation will arise when he will have to choose between saving his own life or that of Morpheus. Returning from the Oracle to a landline phone, which serves as the exit for "red pills" to leave the Matrix, the crew of Morpheus's ship is betrayed by Cypher, a "red pill" who is willing to give the agents Morpheus in exchange for the promise of being mentally erased and reconnected permanently to the Matrix as an escape from the real world's bleakness. In the Matrix, SWAT troops kill Mouse. Cypher jacks out and grabs a real-world lightning gun, injuring Tank and killing Dozer. He kills Apoc and Switch, who remain jacked in, by prematurely terminating their connections. In the Matrix, Smith defeats and captures Morpheus.
=== Wound occlusion === Many animals are able to block off the area around an injury rapidly, by coagulating their blood or body fluid. Invertebrates with hydrostatic skeletons (moving by peristalsis) are unable to move without internal fluid under pressure, while those with an open circulation (body fluid not confined to blood vessels) quickly die from loss of body fluid. In addition, open wounds allow bacteria to enter the body. The invertebrate coagulation system is comparable with the innate immune system (the simpler of two systems of protection against infection) of vertebrates.
Kief is a powder, rich in trichomes, that can be sifted from the leaves, flowers and fruits of cannabis plants and either consumed in powder form or compressed to produce cakes of hashish. The term derives from colloquial Arabic كيف kēf/kīf, meaning pleasure.
Steven Eugene Wilson (born 1951) is an American ophthalmologist and professor at Cleveland Clinic, where he is a surgeon and directs corneal research. He has also received honors for several published historical fiction novels. His research has focused on corneal cellular responses to injury and surgery, with his most-cited work being about keratocyte apoptosis, as well as cellular and molecular interactions involved in homeostasis, wound healing, and diseases of the cornea. He holds two United States patents related to corneal healing. He previously served as a professor and chair of the Department of Ophthalmology at the University of Washington in Seattle from 1998 to 2003, and was named Grace E. Hill Endowed Chair in Vision Research.
When a uranium nucleus fissions into two daughter nuclei fragments, about 0.1 percent of the mass of the uranium nucleus appears as the fission energy of ~200 MeV. For uranium-235 (total mean fission energy 202.79 MeV), typically ~169 MeV appears as the kinetic energy of the daughter nuclei, which fly apart at about 3% of the speed of light, due to Coulomb repulsion. Also, an average of 2.5 neutrons are emitted, with a mean kinetic energy per neutron of ~2 MeV (total of 4.8 MeV). The fission reaction also releases ~7 MeV in prompt gamma ray photons. The latter figure means that a nuclear fission explosion or criticality accident emits about 3.5% of its energy as gamma rays, less than 2.5% of its energy as fast neutrons (total of both types of radiation ~6%), and the rest as kinetic energy of fission fragments (this appears almost immediately when the fragments impact surrounding matter, as simple heat). Some processes involving neutrons are notable for absorbing or finally yielding energy — for example neutron kinetic energy does not yield heat immediately if the neutron is captured by a uranium-238 atom to breed plutonium-239, but this energy is emitted if the plutonium-239 is later fissioned.
Sources: en.wikipedia.org
Ricin is very toxic if inhaled, injected, or ingested. It can also be toxic if dust contacts the eyes or if it is absorbed through damaged skin. It acts as a toxin by inhibiting protein synthesis. Ricin is resistant, but not impervious, to digestion by peptidases. By ingestion, the pathology of ricin is largely restricted to the gastrointestinal tract, where it may cause mucosal injuries. With appropriate treatment, most patients will make a good recovery.
There may also be a secondary mechanism, through which DBNPA’s nitrile group contributes towards its biocidal activity by a potential interaction with other nucleophilic sites like amino groups on proteins or amino acids, however, this mechanism is not widely studied, so not much is known about it. Unlike other similar biocides which require prolonged exposure in order to be effective, like isothiazolinone, DBNPA’s fast reaction is attributed towards its chemical instability in aqueous environments, where it is able to degrade within hours. This instability ensures that microorganisms are exposed to a high initial dose but the likelihood of resistance development is small, since surviving cells are not exposed to sublethal concentrations over extended periods of time. This rapid degradation also means that DBNPA is only well-suited for short-term microbial control, but not long-term preservation, making it serve a different purpose to more stable biocides.
== Specific diseases caused by point mutations == Point mutations—single‑base changes in the DNA sequence—are one of the most common molecular causes of human disease. By altering a single nucleotide, these mutations can substitute one amino acid for another, introduce premature stop codons, or disrupt normal splicing signals. Depending on where they occur and how they affect the encoded protein, point mutations may abolish enzyme activity, destabilize structural domains, or impair regulatory interactions. In many inherited disorders, a single missense or nonsense substitution is enough to trigger a cascade of biochemical failures, leading to early‐onset or lifelong symptoms. In cancer, somatic point mutations can inactivate tumor suppressors or hyperactivate oncogenes, fueling uncontrolled cell growth. Across the human genetic landscape, thousands of point‐mutation–driven conditions have been cataloged—from relatively common disorders like sickle‐cell anemia and cystic fibrosis to extremely rare syndromes that affect only a handful of families worldwide. Although each disease has its own pathophysiological details, they share a unifying theme: a precisely localized change in the gene sequence can compromise protein function in a way that no larger chromosomal rearrangement or copy‐number alteration could. Because point mutations are often amenable to targeted genetic testing, they also highlight how molecular diagnosis and personalized therapies (e.g., small molecules that stabilize a mutant enzyme) rely on knowing exactly which codon is altered.
A five-door hatchback and four-door saloon, both featuring pillarless doors and distinct sheetmetal from other 323s, was sold in Japan as the Mazda Lantis, in Australia, New Zealand and South Africa as the Mazda 323 Astina, in Colombia as the Mazda Allegro and in Europe as the Mazda 323F. They were built on platforms distinct from the other 323s and actually appeared nearly a year before the new Familia, in September 1993. The bodyshape was designed by former Porsche designers. The Lantis was on the CB, a minor update of the CA that underpinned the luxury Mazda Xedos 6 and Eunos 500. The European 323F was designated BA, but was actually almost identical to the CB, and had little to do with other B platforms. These models were sold with the 1.5 L 1.6L and 1.8 L engines seen in the rest of the 323 range, as well as a 2.0 L (KF) V6 shared with the Eunos 500. The 2.0L V6 still remains one of the smallest V6 engines put into a production car.
Sources: en.wikipedia.org
The sequence is Met-Glu-His-Phe-Pro-Gly-Pro, a seven-residue peptide. The first four residues correspond to the ACTH(4-10) fragment, and Pro-Gly-Pro is added at the C-terminus. N-acetylated versions also appear in the literature and differ in mass.
Semax is a synthetic analog of the ACTH(4-10) fragment rather than a copy of the full hormone. Truncation plus the added tail removes the steroidogenic portion of ACTH. That distinction explains why it is studied for nervous-system effects instead of adrenal stimulation.
It is registered as a prescription product in Russia and has been used there clinically, chiefly by the intranasal route. No approval exists in the United States or the European Union. Availability elsewhere typically falls under research-chemical distribution, with varying purity documentation.
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.